You just read:

Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for Treatment of Chronic Low Back Pain

News provided by

Braeburn Pharmaceuticals , Camurus

Sep 30, 2016, 02:00 ET